[go: up one dir, main page]

WO2024049279A3 - Microsphères à libération prolongée contenant du leuprolide, préparation injectable les comprenant, et leur procédé de préparation - Google Patents

Microsphères à libération prolongée contenant du leuprolide, préparation injectable les comprenant, et leur procédé de préparation Download PDF

Info

Publication number
WO2024049279A3
WO2024049279A3 PCT/KR2023/013112 KR2023013112W WO2024049279A3 WO 2024049279 A3 WO2024049279 A3 WO 2024049279A3 KR 2023013112 W KR2023013112 W KR 2023013112W WO 2024049279 A3 WO2024049279 A3 WO 2024049279A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
leuprolide
sustained
same
method therefor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2023/013112
Other languages
English (en)
Korean (ko)
Other versions
WO2024049279A2 (fr
Inventor
이진우
김보연
이주한
설은영
이희용
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
G2gbio Inc
Original Assignee
G2gbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020230059471A external-priority patent/KR102742892B1/ko
Application filed by G2gbio Inc filed Critical G2gbio Inc
Priority to CN202380076927.0A priority Critical patent/CN120152702A/zh
Publication of WO2024049279A2 publication Critical patent/WO2024049279A2/fr
Publication of WO2024049279A3 publication Critical patent/WO2024049279A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des microsphères à libération prolongée contenant une quantité élevée de leuprolide, une préparation injectable la comprenant, et un procédé de préparation associé. Pendant l'administration, le leuprolide est libéré à un niveau suffisant à une étape précoce de telle sorte que les effets du leuprolide sont présentés, ce qui permet une exposition à une quantité suffisante d'un médicament tandis que des réactions inflammatoires et similaires, qui peuvent être problématiques pendant l'administration, sont réduites à un minimum, et ainsi les effets du leuprolide peuvent être présentés en toute sécurité au moins 1 mois.
PCT/KR2023/013112 2022-09-01 2023-09-01 Microsphères à libération prolongée contenant du leuprolide, préparation injectable les comprenant, et leur procédé de préparation Ceased WO2024049279A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202380076927.0A CN120152702A (zh) 2022-09-01 2023-09-01 包含亮丙瑞林的缓释微球、包含其的注射制剂及其制备方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR20220110883 2022-09-01
KR10-2022-0110883 2022-09-01
KR10-2022-0147421 2022-11-07
KR20220147421 2022-11-07
KR10-2023-0059471 2023-05-08
KR1020230059471A KR102742892B1 (ko) 2022-09-01 2023-05-08 류프롤라이드를 포함하는 서방형 미립구, 이를 포함하는 주사제제 및 이의 제조방법

Publications (2)

Publication Number Publication Date
WO2024049279A2 WO2024049279A2 (fr) 2024-03-07
WO2024049279A3 true WO2024049279A3 (fr) 2024-11-07

Family

ID=90098380

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/013112 Ceased WO2024049279A2 (fr) 2022-09-01 2023-09-01 Microsphères à libération prolongée contenant du leuprolide, préparation injectable les comprenant, et leur procédé de préparation

Country Status (2)

Country Link
CN (1) CN120152702A (fr)
WO (1) WO2024049279A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087221A1 (fr) * 2004-03-15 2005-09-22 Christine Allen Implant biocompatible et biodegradable et procede de fabrication de cet implant
KR101113044B1 (ko) * 2008-08-29 2012-02-27 동국제약 주식회사 용매교류증발법에 의한 서방출성 미립구의 제조방법
KR20180131077A (ko) * 2017-05-31 2018-12-10 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
KR20190023314A (ko) * 2017-08-28 2019-03-08 차의과학대학교 산학협력단 전기분무 기술을 이용한 루프롤라이드 함유 서방성 미립구의 제조방법
KR102386163B1 (ko) * 2021-12-03 2022-04-14 (주)인벤티지랩 류프로라이드를 포함하는 마이크로 입자 및 이의 제조 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087221A1 (fr) * 2004-03-15 2005-09-22 Christine Allen Implant biocompatible et biodegradable et procede de fabrication de cet implant
KR101113044B1 (ko) * 2008-08-29 2012-02-27 동국제약 주식회사 용매교류증발법에 의한 서방출성 미립구의 제조방법
KR20180131077A (ko) * 2017-05-31 2018-12-10 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
KR20190023314A (ko) * 2017-08-28 2019-03-08 차의과학대학교 산학협력단 전기분무 기술을 이용한 루프롤라이드 함유 서방성 미립구의 제조방법
KR102386163B1 (ko) * 2021-12-03 2022-04-14 (주)인벤티지랩 류프로라이드를 포함하는 마이크로 입자 및 이의 제조 방법

Also Published As

Publication number Publication date
WO2024049279A2 (fr) 2024-03-07
CN120152702A (zh) 2025-06-13

Similar Documents

Publication Publication Date Title
EP0069259B1 (fr) Forme retard de bromhexine et procédé de préparation
US6117450A (en) Method of making a perorally administered solid drug with controlled effective ingredient delivery
US5439689A (en) Diltiazem formulation
US11723874B2 (en) Delayed release deferiprone tablets and methods of using the same
HK1050487A1 (en) Multiparticulate modified release composition
Speck et al. Bio-availability and pharmacokinetics of cyproterone acetate-14C and ethinyloestradiol-3H after oral administration as a coated tablet (SH B 209 AB)
IE921603A1 (en) Diltiazem formulation
WO2024049279A3 (fr) Microsphères à libération prolongée contenant du leuprolide, préparation injectable les comprenant, et leur procédé de préparation
KR970008157B1 (ko) 나프록센을 함유하는 계획 방출 정제
KR930702961A (ko) 약제학적 조성물
WO2003057278A2 (fr) Systeme d'apport de medicament destine a l'apport continu de glipizide
DE69702985T2 (de) Steroid enthaltende Dosierungsformen mit einer steroiddichten Umhüllung
US4049791A (en) Prolonged acting appetite suppressant and anti-obesity compositions containing amphetamine adipate, dextroamphetamine adipate, amphetamine sulfate and dextroamphetamine sulfate as the active agents
KR20230152051A (ko) 멜라토닌을 포함하는 다층 펠릿의 제형(formulation of a multilayered pellet comprising melatonin)
CN112741827A (zh) 氨己烯酸固体制剂及其制备方法
TW202126289A (zh) 普加巴林的持續-釋放配方
JPS6045162B2 (ja) 抗抑うつ症剤
RU2222318C2 (ru) Композиция для улучшения мозгового кровообращения
Becker et al. Tolerance in Patients with Coronary Heart Disease Under Chronic Treatment with Isosorbide Dinitrate?
WO2002019991A1 (fr) Forme pharmaceutique multiparticualire et son procede de preparation
CN120053386A (zh) 含有贝派地酸和他汀类药物的口服制剂及其制备工艺
Sturtevant et al. Studies on the anti-hypertensive action of 2, 3-diarylalkanonitriles
WO2020121234A1 (fr) Compositions pharmaceutiques orales solides comprenant des matrices monolithiques complexes pour l'administration chronotropique de médicaments dans le tractus gastro-intestinal
US20070185180A1 (en) Pharmaceutical formulation containing phenytoin sodium and magnesium stearate
EA042135B1 (ru) Таблетка деферипрона с отсроченным высвобождением и способ ее изготовления

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23860954

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 202380076927.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 202380076927.0

Country of ref document: CN

122 Ep: pct application non-entry in european phase

Ref document number: 23860954

Country of ref document: EP

Kind code of ref document: A2